Synavant

Sinovant Sciences is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapeutics for the Greater China market. Launched in 2018 as a subsidiary of Roivant Sciences, the company employs a "Vant" model to in-license high-potential assets from global partners and accelerate their clinical development in China. Its lead product, Xenleta (lefamulin), is a first-in-class pleuromutilin antibiotic approved in China for the treatment of community-acquired bacterial pneumonia. The company's pipeline also features derazantinib, a multi-kinase inhibitor targeting FGFR-driven cancers, and naronapride, a 5-HT4 receptor agonist for gastrointestinal disorders. By leveraging its deep local expertise and Roivant's global network, Sinovant aims to address significant unmet medical needs across various therapeutic areas, including infectious diseases, oncology, and rare diseases.